Literature DB >> 7504892

Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma.

P J Mauser1, A Pitman, A Witt, X Fernandez, J Zurcher, T Kung, H Jones, A S Watnick, R W Egan, W Kreutner.   

Abstract

To investigate the role of IL-5 in airway hyperreactivity and pulmonary eosinophilia, we used a model of allergic asthma in guinea pigs and a neutralizing monoclonal antibody (TRFK-5) directed against murine IL-5. Sensitized guinea pigs were challenged with 1% ovalbumin (OVA) aerosol and assessed for airway eosinophilia (by bronchoalveolar lavage [BAL] and histologic evaluation of airway tissue) and bronchoconstrictor responsiveness to substance P (SP) (as RL100 and Cdyn40) 24 h later. OVA challenge of sensitized animals caused a significant increase in airway responsiveness to SP, with a 4.9-fold decrease in RL100 and a 4.7-fold decrease in Cdyn40. Accompanying this increased sensitivity to SP was a 9-fold increase in eosinophils recovered in BAL and a 4- to 5-fold increase in eosinophils in intrapulmonary bronchial tissue. Intraperitoneal treatment with 10 mg/kg of the IL-5 antibody 2 h before OVA challenge blocked BAL and lung tissue increases in eosinophils but had no effect on the development of airway sensitivity to SP. In contrast, similar treatment with 30 mg/kg of this antibody blocked OVA-induced increased sensitivity to SP as well as BAL and lung tissue eosinophilia. These data suggest a critical and possibly independent role for IL-5 in allergic airway hyperresponsiveness and the accumulation of eosinophils within the lung of the guinea pig.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504892     DOI: 10.1164/ajrccm/148.6_Pt_1.1623

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  36 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Effects of anti-IgE in asthmatic subjects.

Authors:  A J Frew
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

3.  The carboxy-terminal region of human interleukin-5 is essential for maintenance of tertiary structure but not for dimerization.

Authors:  A E Proudfoot; S C Brown; P Graber; F Talabot; C Y Arod; M C Peitsch; M Banks; M McKinnon; R Solari; T N Wells
Journal:  J Protein Chem       Date:  1996-07

4.  Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro.

Authors:  E Sato; D K Nelson; S Koyama; J C Hoyt; R A Robbins
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Engineering of a functional interleukin-5 monomer: a paradigm for redesigning helical bundle cytokines with therapeutic potential in allergy and asthma.

Authors:  R R Dickason; J D English; D P Huston
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

7.  Interferon-gamma and antibodies to interleukin-5 and interleukin-4 inhibit the pulmonary eosinophilia in allergic mice.

Authors:  T T Kung; D M Stelts; J A Zurcher; H Jones; S P Umland; R W Egan; W Kreutner; R W Chapman
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

8.  Airway hyperresponsiveness in the absence of CD4+ T cells after primary but not secondary challenge.

Authors:  Anthony Joetham; Katsuyuki Takeda; Christian Taube; Nobuaki Miyahara; Arihiko Kanehiro; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2005-04-21       Impact factor: 6.914

9.  Role of prostaglandin D2 /CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus.

Authors:  Haixia Liu; Mingrui Zheng; Jianou Qiao; Yajie Dang; Pengyu Zhang; Xianqiao Jin
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

10.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.